Literature DB >> 8848988

Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis.

P A Carey1, D J Sheridan, A de Cordoue, D Guez.   

Abstract

Left ventricular hypertrophy is a major risk factor for cardiovascular morbidity and mortality. Angiotensin-converting enzyme inhibitors, calcium antagonists, and beta-blockers prevent, and cause regression of, left ventricular hypertrophy after short-term therapy. The ability of diuretics to do the same is unclear. We have performed a meta-analysis of studies documenting the effect on left ventricular mass of 6 months' treatment with 2.5 mg indapamide daily. Six studies comprising 197 patients, aged 20-75 years, were included. There was an overall mean reduction in left ventricular mass index of 13.3%, which was principally due to a reduction in left ventricular wall thickness rather than internal diameter.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8848988     DOI: 10.1016/s0002-9149(97)89234-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension.

Authors:  George C Roush; Michael E Ernst; John B Kostis; Ramandeep Kaur; Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 2.  Concluding remarks. Pursuit of the optimal outcome in hypertension.

Authors:  L Hansson
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

Review 3.  Clinical implications of indapamide sustained release 1.5 mg in hypertension.

Authors:  R Donnelly
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

Review 4.  Clinical positioning of indapamide sustained release 1.5mg in management protocols for hypertension.

Authors:  G Leonetti
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 5.  Indapamide sustained release: a review of its use in the treatment of hypertension.

Authors:  Dean M Robinson; Keri Wellington
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies.

Authors:  P Weidmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.